This clinical trial is focused on studying a condition known as allergic rhinitis, which is a type of allergy that affects the nose and eyes, often caused by house dust mites. The study aims to evaluate a treatment called subcutaneous cluster-immunotherapy, which involves injecting small doses of an allergen to help the body build up a tolerance. The treatment being tested is called CLU-RX-DPT, which comes in three different doses: low, mid, and high. These doses contain a modified form of the allergen from house dust mites, specifically Dermatophagoides pteronyssinus, which is a common cause of dust mite allergies.

The purpose of the study is to find the most effective and best-tolerated dose of CLU-RX-DPT for people with moderate-to-severe allergic rhinitis due to house dust mites. Participants in the study will receive either one of the doses of CLU-RX-DPT or a placebo, which looks and feels like the treatment but does not contain the active allergen. The study will monitor how well the treatment works in reducing allergy symptoms and the need for other allergy medications over a period of time.

Throughout the study, participants will be asked to keep track of their symptoms and any allergy medications they use. This information will help researchers understand how the treatment affects daily life and overall comfort. The study will also look at how the treatment impacts the quality of life for those with allergic rhinitis. The goal is to determine which dose of CLU-RX-DPT provides the best balance of benefits and side effects for managing symptoms of house dust mite allergies.